MTOR and PTEN hamartoma tumor syndrome: Case reports have described clinical benefit from mammalian target of rapamycin (mTOR) inhibitors in JPI (25,26), PHTS (27) and FAP (23), but their efficacy has not previously been demonstrated in controlled studies.